<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230228057560N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-06</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Treatment of women with constipation and urinary incontinence</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of biofeedback therapy and posterior tibial nerve stimulation alone versus combined treatment on improving pelvic floor muscle activity, sign and quality of life in femals with chronic dyssynergic constipation and  stress urinary incontinence: asingle blind randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>87</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68960</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Health service research, Blinding description: In order to select the participants in this study, we will conduct subsequent sampling through sorting through background variables. We divide people into three groups based on the randomization table. One group receives biofeedback treatment alone, one group receives tibial nerve electrical stimulation treatment alone, and the other group receives combined biofeedback and tibial nerve electrical stimulation treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Constipation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Biofeedback. Intervention 2: Intervention group: Electrical stimulation. Intervention 3: Intervention group: Combination.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Because pelvic floor disorders are taboo</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>fatemeh oraki koohshoori</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 81,6 West Ave., Kyanpars Blvd</address>
        <city>ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6155844474</zip>
        <telephone>+98 61 3391 1287</telephone>
        <email>fatemehorakii@yahoo.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>fatemeh oraki koohshoori</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 81,6 West Ave,, Kyanpars Blvd</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6155844474</zip>
        <telephone>+98 61 3391 1287</telephone>
        <email>fatemehorakii@yahoo.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 18 to 60 
Concomitant presence of constipation and stress urinary incontinence 
At least 12 months have passed since symptoms 
Have not responded to standard medical treatments for constipation and adherence to diet 
not receiveing treatment regarding these two disorders.
Having at least two Criterion of the Rome IV criteria</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unsuccessful history of biofeedback therapy
Uncontrolled cardiovascular, kidney and liver diseases
Back, hip and/or hip joint dysfunction
Diabetes
Chronic obstructive pulmonary disease
Sexual problems
Use of medications (diuretics, sympathomimetics/sympatholytic), parasympathomimetic / parasympatholytic)
Spinal cord injury
Patients with a history of mental illness
Drug-induced constipation
Metabolic, endocrine, neurological disorders
History of pelvic surgery
Pregnancy
Active intestinal disease and fissure
Neurological diseases (such as multiple sclerosis, stroke)
Urine test and positive urine culture
History of radiation therapy or hormone therapy in the last six months
Prolapse of the pelvic organs more than grade 2 (more than 1 cm below Hyman's membrane during the examination in the stretched state of the pelvic floor. Grading will be done through the quantitative system of pelvic organ prolapse and by a gynecologist or pelvic floor physiotherapist. This The method has 5 grades from grade 0 to 4, grade 0 indicates the absence of prolapse, grade 1 is less than 1 cm below Hyman's curtain, grade 2 is more than 1 cm below Hyman's curtain, grade 3 is more than 1 cm. below the hymen, but does not protrude more than 2 cm from the entire length of the vagina, and in grade 4, the lower genital system is completely deviated
They were not able to contract the pelvic floor muscles during finger examination
Active or recurrent urinary tract infection</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Biofeedback</i_keyword>
      <i_keyword>Intervention group: Electrical stimulation</i_keyword>
      <i_keyword>Intervention group: Combination</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Quality of life. Timepoint: At the beginning of treatment, every five sessions, at the end of treatment and three months after treatment. Method of measurement: Questionnaires.</prim_outcome>
      <prim_outcome>Treatment time. Timepoint: At the beginning of treatment, every five sessions, at the end of treatment and three months after treatment. Method of measurement: GEE model.</prim_outcome>
      <prim_outcome>Frequency of incontinence. Timepoint: At the beginning of treatment, every five sessions, at the end of treatment and three months after treatment. Method of measurement: Three day bladder diary.</prim_outcome>
      <prim_outcome>Activity of pelvicfloor muscles. Timepoint: At the beginning of treatment, every five sessions, at the end of treatment and three months after treatment. Method of measurement: Examining the strength, resting tone, resting activity and sneezing or coughing pelvic floor muscles through electromyography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: First session, every five sessions, end of treatment and three months after treatment. Method of measurement: Questionnaires.</sec_outcome>
      <sec_outcome>Pelvic floor muscle activity. Timepoint: First session, every five sessions, end of treatment and three months after treatment. Method of measurement: Electromyography.</sec_outcome>
      <sec_outcome>Treatment time. Timepoint: First session, every five sessions, end of treatment and three months after treatment. Method of measurement: GEE model.</sec_outcome>
      <sec_outcome>Frequency of incontinence. Timepoint: First session, every five sessions, end of treatment and three months after treatment. Method of measurement: Three day bladder diary.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-08</approval_date>
        <contact_name>Ethics committee of Ahwaz Jundi shapoor univercity of medical sciences</contact_name>
        <contact_address>No 81, 6 West Ave, Kyan pars Blvd Ahwaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
